Revenue

The coffee giant posts impressive 2025 results amid high inflation, paving the way for its blockbuster acquisition by Keurig Dr Pepper. What's next?

AEG appoints European veteran John Langford to lead its charge into Asia's booming live entertainment market, a multi-billion dollar bet on new venues.

Forvia reports a €2.1B net loss but shows improved operations and cash flow. Is this strategic pain a necessary step toward long-term gain?

South Korean food giant Daesang signals a major expansion in Japan after a smash debut at a top trade show, targeting the growing taste for authentic kimchi.

With key conferences ahead, Supernus Pharmaceuticals must prove its strategy can deliver growth in the competitive central nervous system drug landscape.

Creatd Inc. executes a 1:20 reverse stock split to chase a national exchange listing. Is it a strategic masterstroke or a sign of deeper struggles?

A new partnership brings an FDA-designated breakthrough device to more patients, fueled by a key Medicare payment that could reshape the trauma market.

The cannabis giant upsizes its credit facility by CAD $15M, signaling strong lender confidence and fueling its ambitious global expansion plans.

The fusion energy pioneer plans to go public via a SPAC merger, seeking capital to prove its unique technology and win the race for limitless clean power.

The hospitality REIT posts a record year, fueled by strong group bookings at its Gaylord hotels and an aggressive expansion into live entertainment markets.

Beam Therapeutics is set to announce its 2025 financial results and a new liver-targeted therapy, a key moment for its base editing platform and investors.

A 1972 Lamborghini Miura SV, held by one owner for over five decades, heads to auction with a $4M estimate, becoming a bellwether for the classic car market.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

A former hedge fund manager's stark video presentation warns that AI will permanently alter work and wealth. Are American workers prepared for what's next?

Following strong earnings and a major SAP settlement, Teradata will detail its AI-driven future and financial outlook at two key investor conferences.

With a new CEO and a key investor conference ahead, Metagenomi bets on its unique metagenomics platform and a hemophilia drug to navigate a tough market.

Top veterinary group endorses Visbiome Vet for chronic gut issues, setting a new evidence-based standard in a crowded, unregulated pet supplement market.

The digital media firm faces a Nasdaq compliance countdown after failing to file its annual report, revealing deeper issues of financial strain and SEC scrutiny.

Fresh off its first profitable year and with a new CEO, Remitly launches a major investor tour to detail its ambitious diversification strategy.

Industrial packaging giant Greif rewards shareholders, but a closer look at its finances and dual-class stock reveals a company in major transition.